The Food and Drug Administration last week revoked its emergency use authorization for a SARS-CoV-2 antibody test made by Autobio Diagnostics Co. due to concerns with the accuracy of the test when evaluated at the National Institutes of Health’s Frederick National Laboratory for Cancer Research.

“Specifically, the Agency has concluded that it is unlikely that this test is effective in detecting SARS-COV-2 IgM antibodies and that the known and potential benefits of its use do not outweigh the known and potential risks,” the agency said.

 

Related News Articles

Headline
In this AHA Advancing Health podcast, Sara Jumping Eagle, M.D., and Jonathan Merrell, R.N., both of the Indian Health Service, discuss plans to reduce the…
Headline
The COVID-19 pandemic has spurred a number of innovations in health care delivery that have the potential to positively alter how care is provided, and…
Headline
Health leaders from across the U.S. convened to discuss the unique challenges facing rural communities and providers in addressing COVID-19 vaccine…
Headline
The Department of Health and Human Services has renewed the COVID-19 public health emergency declaration for another 90 days effective April 21. The extension…
Blog
A panel of rural health care experts and other health care leaders assembled by the AHA and the Black Coalition Against COVID-19 convened April 21 at 7 p.m. ET…
Headline
President Biden today announced that the nation has administered its 200 millionth COVID-19 vaccine dose, a milestone reached earlier than projected when…